Twist Bioscience Publishes Preclinical Data In Diabetes Validating GLP-1R Antagonist Antibody As Potential Treatment For Congenital Hyperinsulinism
Portfolio Pulse from Benzinga Newsdesk
Twist Bioscience has published preclinical data validating its GLP-1R antagonist antibody, TB-222-023, as a potential treatment for congenital hyperinsulinism. The antibody was discovered and optimized using Twist's synthetic DNA libraries and antibody engineering services.
June 26, 2023 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Twist Bioscience's preclinical data on GLP-1R antagonist antibody may boost investor confidence in the company's product pipeline.
The preclinical data validates Twist Bioscience's GLP-1R antagonist antibody as a potential treatment for congenital hyperinsulinism. This positive news may increase investor confidence in the company's product pipeline, potentially leading to a short-term increase in stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100